Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 13.12.2023
MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG
(ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 62,00.
Zusammenfassung:
Der NAVPS lag zum Neunmonatszeitpunkt bei €50,40 gegenüber €31,90 in 9M/22
(+58%) Die schlep [ … ]
Tue, 12.12.2023
Kondike Gold Corp
First Berlin Equity Research hat ein Research Update zu Klondike Gold Corp.
(ISIN: CA4989033010) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von CAD 0,75.
Zusammenfassung:
Der Nachrichtenfluss hat in letzter Zeit zugenommen, wobei die Ergebnisse
von Gay Gulch aus der Exploration [ … ]
Mon, 11.12.2023
Advanced Blockchain AG
Expected increase in profitability
Advanced Blockchain AG was recently presented at the Eigenkapitalforum by
CEO Simon Telian and Sebastian Markowsky, which met with considerable
interest from investors. Initial plans for 2024 have been communicated.
Assuming that the current very positive trend in the crypto market
continues, the manageme [ … ]
Thu, 07.12.2023
Mexedia SPA-SB
Pioneering Tomorrow's Tech Landscape: Mexedia's Visionary Journey Unfolds
The MKK Conference in Munich has provided the backdrop for a compelling
conversation between the Mexedia's CEO, Orlando Taddeo, and equity research
analyst Matthias Greiffenberger. Against the vibrant atmosphere of one of
Germany’s leading conferences, this int [ … ]
Thu, 07.12.2023
Media and Games Invest SE
Nine months 2023: Solid sales and operating earnings performance despite
challenging conditions; positive effects from the initiated savings
programme enabled an increase in profitability; GBC estimates and price
target confirmed
Business performance 9M 2023
Media and Games Invest (SE) published its nine-month and Q3 figures for the [ … ]
Thu, 07.12.2023
Media & Games Invest SE
First Berlin Equity Research hat ein Research Update zu Media and Games
Invest SE (ISIN: SE0018538068) veröffentlicht. Analyst Ellis Acklin
bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 3,20.
Zusammenfassung:
Das dritte Quartal verlief ähnlich wie der vorangegangene
Dreimonatszeitraum, wobei die Topline [ … ]
Thu, 07.12.2023
Marley Spoon Group SE
RS feedback: Venture-like D2C meal kit opportunity
Yesterday, we hosted a digital roadshow with the CEO of Marley Spoon. Here
are our key takeaways:
Adjusted voucher strategy and turnaround. In Q3, the company rectified a
previously changed voucher strategy and has already seen promising signs of
increasing marketing efficiency and early coho [ … ]
Wed, 06.12.2023
Mexedia SPA-SB
Advancing Mexedia: Expanding Services, Strategic Acquisitions, and
Innovative Offerings
During the first half of 2023, the Mexedia Group witnessed a substantial
surge in revenue propelled by strategic acquisitions of Phonetime Inc. and
Matchcom Telecommunications Inc., executed through Mexedia Inc. These
acquisitions strategically redirect [ … ]
Wed, 06.12.2023
123fahrschule SE
Sound Q3 confirms positive momentum
123fahrschule published a sound set of Q3 results, showing continuous
top-line growth and a significantly improved profitability. Here are the
key takeaways:
Q3 sales increased by 23% yoy to € 5.2m (eNuW: € 5.1m) driven by a
significantly increased number of overall driving lessons (+19% to 146k) [ … ]
Tue, 05.12.2023
CEL-SCI Corporation
First Berlin Equity Research has initiated coverage on CEL-SCI Corporation
(ISIN: US1508376076). Analyst Christian Orquera's rating is BUY with a
price target of USD 8.40 (€7.70).
Abstract:
CEL-SCI Corporation (CEL-SCI) is a biotech company with a development-stage
immunotherapeutic product pipeline focused on cancer. The company's lead
dr [ … ]
